Plasmotest mycoplasma detection kit

Manufactured by Thermo Fisher Scientific

Sourced in United States

PlasmoTest Mycoplasma detection kits are designed to detect the presence of mycoplasma contamination in cell cultures. They provide a reliable and rapid method for mycoplasma testing.

Automatically generated - may contain errors

Lab products found in correlation

Rpmi medium, by Thermo Fisher Scientific (1 mentions) Hcc1937, by American Type Culture Collection (1 mentions) Mda mb 231, by American Type Culture Collection (1 mentions) Bt549, by American Type Culture Collection (1 mentions) Leibovitz s l 15 medium, by American Type Culture Collection (1 mentions) Bt 20, by American Type Culture Collection (1 mentions) Mda mb 453, by American Type Culture Collection (1 mentions) Vitamin c, by Merck Group (1 mentions)

Close spelling variants of this product

Mycoplasma detection kit PlasmoTest™ Kit PlasmoTest

4 protocols using plasmotest mycoplasma detection kit

Triple-Negative Breast Cancer Cell Culture

Check if the same lab product or an alternative is used in the 5 most similar protocols

TNBC cell lines including MDA-MB-231, BT-549, and HCC1937 were purchased from ATCC (Manassas, VA) in a period between the year of 2013 to 2016 without further authentication. Frozen cells were newly thawed from low (3−10) passages. Testing for Mycoplasma was performed using PlasmoTest Mycoplasma detection kits (Thermo Fisher, Waltham, MA) and only negative cells were included in all experiments. All cells were maintained under a 5% CO₂ atmosphere in RPMI medium (Life technologies, Carlsbad, CA) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 Units/mL penicillin, and 100 μg/mL of streptomycin. DT-28 cells, which were maintained in IMEM with 10% FBS as described previously [27 (link)], were a kind gift from Dr. Dorraya El-Ashry (University of Minnesota). TNBC cells were seeded for 24 h and subsequently treated with vitamin C (sodium ascorbate, Sigma-Aldrich, St. Louis, MO). Media was changed daily to ensure the presence of fresh vitamin C.

Mustafi S., Camarena V., Qureshi R., Yoon H., Volmar C.H., Huff T.C., Sant D.W., Zheng L., Brothers S.P., Wahlestedt C., Slingerland J, & Wang G. (2019). Vitamin C supplementation expands the therapeutic window of BETi for triple negative breast cancer. EBioMedicine, 43, 201-210.

+ Open protocol

+ Expand

Evaluating Vitamin C and PI3K Inhibitors on TNBC Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

TNBC cell lines including BT20 and MDA-MB-453, which both carry activating PIK3CA mutations, were purchased from ATCC (Manassas, VA) in the year of 2018 without further authentication. Frozen cells were newly thawed from low (2-5) passages. Testing for mycoplasma was performed using PlasmoTest Mycoplasma detection kits (Thermo Fisher, Waltham, MA) with only mycoplasma negative cells included in all experiments. BT20 cells were maintained under a 5% CO₂ atmosphere in Eagle's Minimum Essential Medium (EMEM), while MDA-MB-453 cells were cultured in Leibovitz's L-15 Medium (ATCC), supplemented with 10% heat-inactivated fetal bovine serum, 100 Units/ ml penicillin, and 100 μg/ml of streptomycin. TNBC cells were seeded for 24 hours and subsequently treated with vitamin C (sodium ascorbate, Sigma-Aldrich, St. Louis, MO) and different PI3K inhibitors at various concentrations. Media was changed daily to ensure the presence of fresh vitamin C.

Mustafi S., Camarena V., Qureshi R., Sant D.W., Wilkes Z., Bilbao D., Slingerland J., Kesmodel S.B, & Wang G. (2021). Vitamin C sensitizes triple negative breast cancer to PI3K inhibition therapy. Theranostics, 11(8), 3552-3564.

+ Open protocol

+ Expand

Ascorbate exposure in cell culture

Check if the same lab product or an alternative is used in the 5 most similar protocols

Stock cells were maintained in DMEM supplemented with 10% complete (non-dialyzed) fetal bovine serum (cFBS). For experimental purposes, cells were seeded and grown in DMEM supplemented with 10% dialyzed fetal bovine serum (dFBS). Cells were seeded in at a packed-cell volume (PCV) of 0.25 µL/mL and grown to approximately 70–80% confluence. Comparable cell density was confirmed both visually under a microscope and by cell count using a Countess II Hemocytometer. Cells were routinely tested for mycoplasma contamination using the PlasmoTest Mycoplasma Detection Kit (Invitrogen).
One hour prior to ascorbate exposure, blank media was pre-equilibrated for temperature and pH in a 5% CO₂ incubator at 37 °C. Growth media was aspirated, equilibrated media was spiked with ascorbate and/or other indicated compounds, and the fresh, spiked media was applied to cells for the time indicated.

Jankowski C.S, & Rabinowitz J.D. (2022). Selenium modulates cancer cell response to pharmacologic ascorbate. Cancer research, 82(19), 3486-3498.

+ Open protocol

+ Expand

Cell Maintenance and Passaging for MDA-MB-231 BO and AT3 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

MDA-MB-231 BO and AT3 (ATCC CRL-2375) cells were maintained in DMEM supplemented with 10% FBS and 1% GlutaMAX. Cells were cultured at 37 °C and 5% CO₂, and experiments were conducted on cells that were passaged at least twice after thawing from the frozen stock. Cells were used until 12 subsequent passages and the new frozen stock was thawed afterwards. Cells were routinely tested negative for mycoplasma contamination by using a PlasmoTest™ Mycoplasma Detection Kit (rep-pt1, Invitrogen, San Diego, CA, USA).

Kaur I., Tieu T., Deepagan V.G., Ali M.A., Alsunaydih F., Rudd D., Moghaddam M.A., Bourgeois L., Adams T.E., Thurecht K.J., Yuce M., Cifuentes-Rius A, & Voelcker N.H. (2023). Combination of Chemotherapy and Mild Hyperthermia Using Targeted Nanoparticles: A Potential Treatment Modality for Breast Cancer. Pharmaceutics, 15(5), 1389.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!